Dr Naval Daver is Associate Professor and Director of the Leukemia Research Alliance Program in the Leukemia Department at the MD Anderson Cancer Center (MDACC) in Houston, TX. He is a clinical investigator with a focus on molecular and immune therapies in acute myeloid leukaemia (AML) and myeloid disease, and is Principal Investigator on more than 25 ongoing institutional, national and international clinical trials in these diseases, including multiple registration and label-enabling trials.

These trials focus on developing a personalised therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanisms of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint, CD47, NK and T-cell based approaches, as well as combinations of targeted and apoptotic therapies in AML, and he is leading a number of these trials at MDACC. Dr Daver has published more than 400 peer-reviewed manuscripts and is on the editorial board of numerous haematology journals. He also serves as Chair on numerous national and international meetings and educational platforms.